Market Closed -
Euronext Amsterdam
16:35:24 26/04/2024 BST
|
Pre-market
07:36:11
|
26.68
EUR
|
+0.45%
|
|
26.89
|
+0.79%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
12,060
|
5,264
|
3,227
|
2,722
|
2,438
|
1,758
|
-
|
-
|
Enterprise Value (EV)
1 |
6,305
|
102.9
|
-1,450
|
2,722
|
-1,237
|
-1,676
|
-1,368
|
-889.7
|
P/E ratio
|
74.9
x
|
-17.2
x
|
-31.2
x
|
-12.5
x
|
11.5
x
|
-27.9
x
|
-20.4
x
|
-11.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
13.5
x
|
9.93
x
|
6.65
x
|
5.39
x
|
3.11
x
|
5.21
x
|
5.59
x
|
5.72
x
|
EV / Revenue
|
7.04
x
|
0.19
x
|
-2.99
x
|
5.39
x
|
-1.58
x
|
-4.97
x
|
-4.35
x
|
-2.89
x
|
EV / EBITDA
|
16.5
x
|
-0.64
x
|
11.1
x
|
-13.5
x
|
-
|
14.6
x
|
10.1
x
|
4.77
x
|
EV / FCF
|
1.98
x
|
-0.22
x
|
2.65
x
|
-
|
2.91
x
|
5.49
x
|
4.28
x
|
1.8
x
|
FCF Yield
|
50.5%
|
-457%
|
37.8%
|
-
|
34.4%
|
18.2%
|
23.4%
|
55.6%
|
Price to Book
|
4.19
x
|
1.97
x
|
1.22
x
|
-
|
-
|
0.65
x
|
0.67
x
|
0.91
x
|
Nbr of stocks (in thousands)
|
64,667
|
65,412
|
65,553
|
65,836
|
65,897
|
65,897
|
-
|
-
|
Reference price
2 |
186.5
|
80.48
|
49.22
|
41.35
|
36.99
|
26.68
|
26.68
|
26.68
|
Announcement Date
|
20/02/20
|
18/02/21
|
24/02/22
|
23/02/23
|
22/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
895.6
|
530.3
|
484.8
|
505.3
|
783.5
|
337.3
|
314.4
|
307.6
|
EBITDA
1 |
382.7
|
-160
|
-131
|
-202
|
-
|
-114.7
|
-135.7
|
-186.7
|
EBIT
1 |
370.3
|
-178.6
|
-165.6
|
-267.5
|
129
|
-119.2
|
-139.5
|
-163.2
|
Operating Margin
|
41.35%
|
-33.68%
|
-34.15%
|
-52.94%
|
16.46%
|
-35.35%
|
-44.36%
|
-53.05%
|
Earnings before Tax (EBT)
1 |
150.1
|
-309.8
|
-123
|
-215.1
|
-
|
-33.42
|
-58.47
|
-96.03
|
Net income
1 |
149.8
|
-305.4
|
-103.2
|
-218
|
211.7
|
-43.95
|
-65.24
|
-95.07
|
Net margin
|
16.73%
|
-57.59%
|
-21.29%
|
-43.14%
|
27.02%
|
-13.03%
|
-20.75%
|
-30.91%
|
EPS
2 |
2.490
|
-4.690
|
-1.580
|
-3.320
|
3.210
|
-0.9578
|
-1.306
|
-2.269
|
Free Cash Flow
1 |
3,186
|
-469.9
|
-547.7
|
-
|
-425.2
|
-305.2
|
-319.5
|
-494.8
|
FCF margin
|
355.77%
|
-88.6%
|
-112.97%
|
-
|
-54.27%
|
-90.49%
|
-101.64%
|
-160.88%
|
FCF Conversion (EBITDA)
|
832.48%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
2,126.99%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20/02/20
|
18/02/21
|
24/02/22
|
23/02/23
|
22/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
64.19
|
143.4
|
144
|
137.7
|
274
|
136.2
|
95.12
|
178.9
|
150
|
120
|
334.7
|
82.92
|
60.66
|
61.15
|
59.67
|
64.63
|
EBITDA
|
-70.14
|
15.79
|
-
|
-44.04
|
-
|
-
|
-110.8
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-78.2
|
10.2
|
-21.1
|
-76.4
|
-97.5
|
-37.6
|
-132.5
|
21.97
|
-10.69
|
-30.23
|
148
|
-36.44
|
-34.09
|
-30.46
|
-37.36
|
-11.88
|
Operating Margin
|
-121.82%
|
7.11%
|
-14.65%
|
-55.48%
|
-35.58%
|
-27.61%
|
-139.26%
|
12.28%
|
-7.13%
|
-25.19%
|
44.21%
|
-43.94%
|
-56.19%
|
-49.81%
|
-62.61%
|
-18.38%
|
Earnings before Tax (EBT)
1 |
-64.46
|
19.09
|
-11.6
|
-18.22
|
-
|
22.25
|
-207.6
|
23.46
|
18.46
|
25.73
|
-
|
-8.613
|
-5.09
|
-3.95
|
-12.63
|
3.86
|
Net income
1 |
-64.6
|
16.37
|
-13.3
|
-19
|
-
|
21.5
|
-207.2
|
23.21
|
5.101
|
25.83
|
157.6
|
-8.613
|
-5.09
|
-3.95
|
-12.63
|
3.86
|
Net margin
|
-100.63%
|
11.41%
|
-9.24%
|
-13.8%
|
-
|
15.79%
|
-217.84%
|
12.97%
|
3.4%
|
21.52%
|
47.08%
|
-10.39%
|
-8.39%
|
-6.46%
|
-21.17%
|
5.97%
|
EPS
|
-0.9900
|
0.2500
|
-
|
-0.2900
|
-
|
0.3300
|
-3.160
|
-
|
0.0800
|
0.3900
|
2.390
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/11/21
|
24/02/22
|
05/05/22
|
04/08/22
|
04/08/22
|
03/11/22
|
23/02/23
|
04/05/23
|
03/08/23
|
02/11/23
|
22/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
5,755
|
5,161
|
4,676
|
-
|
3,675
|
3,434
|
3,127
|
2,648
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
3,186
|
-470
|
-548
|
-
|
-425
|
-305
|
-320
|
-495
|
ROE (net income / shareholders' equity)
|
16.2%
|
-11%
|
-3.89%
|
-
|
7.96%
|
-1.36%
|
-1.85%
|
-3.32%
|
ROA (Net income/ Total Assets)
|
8.82%
|
-5.18%
|
-1.89%
|
-
|
4.66%
|
-1.03%
|
-1.95%
|
-5.39%
|
Assets
1 |
1,698
|
5,892
|
5,455
|
-
|
4,546
|
4,260
|
3,345
|
1,763
|
Book Value Per Share
2 |
44.50
|
40.80
|
40.30
|
-
|
-
|
41.30
|
39.80
|
29.40
|
Cash Flow per Share
2 |
53.40
|
-6.530
|
-7.530
|
-
|
-
|
-2.970
|
-2.980
|
-4.330
|
Capex
1 |
22.4
|
42.5
|
54.2
|
-
|
19.3
|
32.3
|
37.1
|
30.2
|
Capex / Sales
|
2.5%
|
8.02%
|
11.18%
|
-
|
2.46%
|
9.58%
|
11.8%
|
9.82%
|
Announcement Date
|
20/02/20
|
18/02/21
|
24/02/22
|
23/02/23
|
22/02/24
|
-
|
-
|
-
|
Last Close Price
26.68
EUR Average target price
38.43
EUR Spread / Average Target +44.04% Consensus |
1st Jan change
|
Capi.
|
---|
| -27.87% | 1.88B | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|